Skip to content

Application of ctDNA methylated liquid biopsy in the screening of postoperative recurrence of colorectal cancer with liver metastasis and evaluation of adjuvant therapy

Application of ctDNA methylated liquid biopsy in the screening of postoperative recurrence of colorectal cancer with liver metastasis and evaluation of adjuvant therapy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037550
Enrollment
Unknown
Registered
2020-08-28
Start date
2021-01-01
Completion date
Unknown
Last updated
2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer with liver metastasis

Interventions

Gold Standard:Clinical outcome
biopsy

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Subjects were required to meet all of the following criteria to be eligible for the study: The age ranged from 18 to 80 years old; Liver metastasis was confirmed by pathological diagnosis; Complete resection of primary and metastatic colorectal cancer (R0); The general condition of the patients after operation was allowed to receive chemotherapy; The expected survival time was more than 6 months; There are enough surgical or biopsy specimens for gene detection; Subjects (or their legal representatives / guardians) must sign informed consent to indicate that they understand the purpose of the study, understand the necessary procedures for the study, and are willing to participate in the study.

Exclusion criteria

Exclusion criteria: Those with one or more of the following are not eligible for this study: Active bleeding with clinical significance; Alcoholism or drug addiction; Important organ failure or other serious diseases, including clinical related coronary artery disease, cardiovascular disease or myocardial infarction, congestive heart failure, unstable angina pectoris, obvious pericardial effusion or unstable arrhythmia within 6 months before enrollment; Severe neurological or psychiatric history; severe infection; active disseminated intravascular coagulation or other accompanying diseases that, according to the investigator's judgment, seriously endanger the safety of the patient or affect the patient's completion of the study.

Design outcomes

Primary

MeasureTime frame
ctDNA;

Countries

China

Contacts

Public ContactZhu Weiping

Fudan University Shanghai Cancer Center

wpzhush@126.com+86 18017317486

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026